The NHS has secured a groundbreaking 12-year deal to introduce Mounjaro, a promising new weight-loss injection, marking a significant step forward in tackling Britain's obesity crisis. This long-term framework agreement will enable a carefully managed rollout of tirzepatide—the drug's active ingredient—offering new hope for thousands of adults struggling with obesity across the UK.
Mounjaro has received approval for adults with a Body Mass Index (BMI) of 30 or above, as well as those with a BMI between 27 and 29.9 who also have weight-related health conditions such as type 2 diabetes or high blood pressure. The medication works by mimicking two natural gut hormones—GLP-1 and GIP—which help regulate both appetite and blood sugar levels. This dual action effectively reduces hunger and food intake, supporting sustainable weight loss.
The National Institute for Health and Care Excellence (NICE) recommended Mounjaro earlier this year for people who haven't achieved sufficient weight loss through diet and exercise alone, and who meet the specific BMI criteria. The treatment involves a weekly injection and must be used alongside a reduced-calorie diet and increased physical activity—it's not a standalone solution.
The 12-year timeframe reflects the NHS's commitment to introducing high-demand treatments responsibly. This extended agreement allows for proper planning of supply chains, training for healthcare professionals, and establishing clear patient pathways. It's a sensible approach that acknowledges both the potential of this treatment and the scale of obesity challenges facing the UK.
However, patients shouldn't expect immediate access. The rollout will be phased and carefully managed, with Mounjaro initially available only through specialist NHS weight management services rather than directly from GPs. This ensures the drug reaches those who will benefit most and receives appropriate medical supervision throughout treatment.
With approximately 25.9% of adults in England living with obesity according to NHS Digital, the stakes are high. Obesity contributes to serious conditions including type 2 diabetes, heart disease, stroke, and certain cancers. While Mounjaro offers genuine hope, it remains part of a comprehensive approach that prioritises lifestyle changes. Anyone considering weight management options should speak with their GP or contact NHS 111 for guidance on the support available to them.